Severe bradycardia: An unreported adverse infusion-associated reaction (IAR) with alemtuzumab.
CHU de Nîmes, Department of Neurology, 9, place du Pr Robert Debré, Nîmes Cedex 9, 30029, France. Electronic address: nerrant.elodie@gmail.com.
E
E
Nerrant
CHU de Nîmes, Department of Neurology, 9, place du Pr Robert Debré, Nîmes Cedex 9, 30029, France; Institut de Génomique Fonctionnelle, Neurosciences, 141, rue de la Cardonille, Montpellier cedex 5, 34294, France.
E
E
Thouvenot
CHU de Nîmes, Department of Neurology, 9, place du Pr Robert Debré, Nîmes Cedex 9, 30029, France.
G
G
Castelnovo
D000328:Adult; D000074323:Alemtuzumab / Q000009:adverse effects* / Q000627:therapeutic use; D001919:Bradycardia / Q000139:chemically induced*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications / Q000188:drug therapy
D000074323:Alemtuzumab